Literature DB >> 33275901

Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development.

Katherine A Donovan1, Fleur M Ferguson1, Jonathan W Bushman1, Nicholas A Eleuteri2, Debabrata Bhunia3, SeongShick Ryu4, Li Tan5, Kun Shi6, Hong Yue1, Xiaoxi Liu1, Dennis Dobrovolsky1, Baishan Jiang1, Jinhua Wang1, Mingfeng Hao1, Inchul You1, Mingxing Teng1, Yanke Liang1, John Hatcher1, Zhengnian Li1, Theresa D Manz7, Brian Groendyke1, Wanyi Hu2, Yunju Nam8, Sandip Sengupta9, Hanna Cho8, Injae Shin4, Michael P Agius10, Irene M Ghobrial10, Michelle W Ma1, Jianwei Che1, Sara J Buhrlage1, Taebo Sim11, Nathanael S Gray12, Eric S Fischer13.   

Abstract

Targeted protein degradation (TPD) refers to the use of small molecules to induce ubiquitin-dependent degradation of proteins. TPD is of interest in drug development, as it can address previously inaccessible targets. However, degrader discovery and optimization remains an inefficient process due to a lack of understanding of the relative importance of the key molecular events required to induce target degradation. Here, we use chemo-proteomics to annotate the degradable kinome. Our expansive dataset provides chemical leads for ∼200 kinases and demonstrates that the current practice of starting from the highest potency binder is an ineffective method for discovering active compounds. We develop multitargeted degraders to answer fundamental questions about the ubiquitin proteasome system, uncovering that kinase degradation is p97 dependent. This work will not only fuel kinase degrader discovery, but also provides a blueprint for evaluating targeted degradation across entire gene families to accelerate understanding of TPD beyond the kinome.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  E3 ligase; IMiD; PROTAC; degrader; kinase; targeted degradation; ubiquitin; ubiquitin proteasome system

Mesh:

Substances:

Year:  2020        PMID: 33275901     DOI: 10.1016/j.cell.2020.10.038

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  30 in total

Review 1.  The PROTACtable genome.

Authors:  Melanie Schneider; Chris J Radoux; Andrew Hercules; David Ochoa; Ian Dunham; Lykourgos-Panagiotis Zalmas; Gerhard Hessler; Sven Ruf; Veerabahu Shanmugasundaram; Michael M Hann; Pam J Thomas; Markus A Queisser; Andrew B Benowitz; Kris Brown; Andrew R Leach
Journal:  Nat Rev Drug Discov       Date:  2021-07-20       Impact factor: 84.694

2.  Selective degradation-inducing probes for studying cereblon (CRBN) biology.

Authors:  Chelsea E Powell; Guangyan Du; Jonathan W Bushman; Zhixiang He; Tinghu Zhang; Eric S Fischer; Nathanael S Gray
Journal:  RSC Med Chem       Date:  2021-07-06

Review 3.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 4.  Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer.

Authors:  Francesco Davide Naso; Dalila Boi; Camilla Ascanelli; Georgiana Pamfil; Catherine Lindon; Alessandro Paiardini; Giulia Guarguaglini
Journal:  Oncogene       Date:  2021-05-13       Impact factor: 9.867

5.  Targeted protein degraders: a call for collective action to advance safety assessment.

Authors:  Lyn H Jones; Constance A Mitchell; Lise Loberg; Mira Pavkovic; Mohan Rao; Ruth Roberts; Katie Stamp; Laurie Volak; Matthias B Wittwer; Syril Pettit
Journal:  Nat Rev Drug Discov       Date:  2022-06       Impact factor: 84.694

6.  Ligandability of E3 Ligases for Targeted Protein Degradation Applications.

Authors:  Bridget P Belcher; Carl C Ward; Daniel K Nomura
Journal:  Biochemistry       Date:  2021-09-02       Impact factor: 3.162

7.  A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders.

Authors:  Patrick D Fischer; Evangelos Papadopoulos; Jon M Dempersmier; Zi-Fu Wang; Radosław P Nowak; Katherine A Donovan; Joann Kalabathula; Christoph Gorgulla; Pierre P M Junghanns; Eihab Kabha; Nikolaos Dimitrakakis; Ognyan I Petrov; Constantine Mitsiades; Christian Ducho; Vladimir Gelev; Eric S Fischer; Gerhard Wagner; Haribabu Arthanari
Journal:  Eur J Med Chem       Date:  2021-04-08       Impact factor: 7.088

Review 8.  Trends in kinase drug discovery: targets, indications and inhibitor design.

Authors:  Misty M Attwood; Doriano Fabbro; Aleksandr V Sokolov; Stefan Knapp; Helgi B Schiöth
Journal:  Nat Rev Drug Discov       Date:  2021-08-05       Impact factor: 84.694

Review 9.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

10.  Chemo-proteomics exploration of HDAC degradability by small molecule degraders.

Authors:  Yuan Xiong; Katherine A Donovan; Nicholas A Eleuteri; Nadia Kirmani; Hong Yue; Anthony Razov; Noah M Krupnick; Radosław P Nowak; Eric S Fischer
Journal:  Cell Chem Biol       Date:  2021-07-26       Impact factor: 9.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.